These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16293295)

  • 1. Animal models of cognitive dysfunction.
    Tayebati SK
    Mech Ageing Dev; 2006 Feb; 127(2):100-8. PubMed ID: 16293295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models of Alzheimer's Parkinson's and Huntington's disease. A minireview.
    Antal A; Bodis-Wollner I
    Neurobiology (Bp); 1993; 1(2):101-22. PubMed ID: 8111350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid.
    Giménez-Llort L; Blázquez G; Cañete T; Johansson B; Oddo S; Tobeña A; LaFerla FM; Fernández-Teruel A
    Neurosci Biobehav Rev; 2007; 31(1):125-47. PubMed ID: 17055579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular cognitive impairment: dementia biology and translational animal models.
    Barone FC; Rosenbaum DM; Zhou J; Crystal H
    Curr Opin Investig Drugs; 2009 Jul; 10(7):624-37. PubMed ID: 19579168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexisting cholinergic and parahippocampal degeneration: a key to memory loss in dementia and a challenge for transgenic models?
    Cassel JC; Mathis C; Majchrzak M; Moreau PH; Dalrymple-Alford JC
    Neurodegener Dis; 2008; 5(5):304-17. PubMed ID: 18520165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic deletion or antagonism of kinin B(1) and B(2) receptors improves cognitive deficits in a mouse model of Alzheimer's disease.
    Prediger RD; Medeiros R; Pandolfo P; Duarte FS; Passos GF; Pesquero JB; Campos MM; Calixto JB; Takahashi RN
    Neuroscience; 2008 Feb; 151(3):631-43. PubMed ID: 18191900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of cyclooxygenase inhibitors on intracerebroventricular colchicine-induced dysfunction and oxidative stress in rats.
    Kumar A; Seghal N; Padi SV; Naidu PS
    Eur J Pharmacol; 2006 Dec; 551(1-3):58-66. PubMed ID: 17027965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Depression and frontal dysfunction: risks for the elderly?].
    Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP
    Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study.
    Rockwood K; Moorhouse PK; Song X; MacKnight C; Gauthier S; Kertesz A; Montgomery P; Black S; Hogan DB; Guzman A; Bouchard R; Feldman H;
    J Neurol Sci; 2007 Jan; 252(2):106-12. PubMed ID: 17189642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the Ubiquilin 1 gene with Alzheimer's and Parkinson's disease and cognitive function.
    Arias-Vásquez A; de Lau L; Pardo L; Liu F; Feng BJ; Bertoli-Avella A; Isaacs A; Aulchenko Y; Hofman A; Oostra B; Breteler M; van Duijn C
    Neurosci Lett; 2007 Aug; 424(1):1-5. PubMed ID: 17709205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Disease: astrocytes in neurodegenerative disease.
    Maragakis NJ; Rothstein JD
    Nat Clin Pract Neurol; 2006 Dec; 2(12):679-89. PubMed ID: 17117171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment.
    Griffith HR; Stewart CC; den Hollander JA
    Int Rev Neurobiol; 2009; 84():105-31. PubMed ID: 19501715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium.
    Duara R; Barker W; Loewenstein D; Bain L
    Alzheimers Dement; 2009 Jan; 5(1):66-74. PubMed ID: 19118811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research.
    Pryce CR; Rüedi-Bettschen D; Dettling AC; Weston A; Russig H; Ferger B; Feldon J
    Neurosci Biobehav Rev; 2005; 29(4-5):649-74. PubMed ID: 15925698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease?
    Bons N; Rieger F; Prudhomme D; Fisher A; Krause KH
    Genes Brain Behav; 2006 Mar; 5(2):120-30. PubMed ID: 16507003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
    Chen JF; Sonsalla PK; Pedata F; Melani A; Domenici MR; Popoli P; Geiger J; Lopes LV; de Mendonça A
    Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic nonhuman primates for neurodegenerative diseases.
    Chan AW
    Reprod Biol Endocrinol; 2004 Jun; 2():39. PubMed ID: 15200672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive-behavioral profiles of neurodegenerative dementias: beyond Alzheimer's disease.
    Levy JA; Chelune GJ
    J Geriatr Psychiatry Neurol; 2007 Dec; 20(4):227-38. PubMed ID: 18004009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model.
    Bharathi ; Shamasundar NM; Sathyanarayana Rao TS; Dhanunjaya Naidu M; Ravid R; Rao KS
    Brain Res Rev; 2006 Sep; 52(2):275-92. PubMed ID: 16782202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.